Diabetes and stroke: Part one - Risk factors and pathophysiology

Current Cardiology Reports

Volumn 8, Issue 1, 2006, Pages 23-28

  Baliga, Bantwal Suresh ^a   Weinberger, Jesse ^b  

^a NORTH GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATENOLOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; GLUCOSE; HEXOSAMINE; HYDROCHLOROTHIAZIDE; ISOPROTEIN; LOSARTAN; PROTEIN KINASE C; RAMIPRIL; SIMVASTATIN;

BRAIN DISEASE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GREAT BLOOD VESSEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROANGIOPATHY; MORTALITY; NECROSIS; PATHOPHYSIOLOGY; PREVALENCE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

CEREBROVASCULAR ACCIDENT; DIABETES COMPLICATIONS; HUMANS; HYPERGLYCEMIA; METABOLIC SYNDROME X; RISK FACTORS;

EID: 33645077624     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-006-0006-1     Document Type: Review

References (80)

1. Rosamond WD, Folsom AR, Chambless LE, et al.: Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999, 30:736-743.
2. American Heart Association: 2001 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2001.
3. Murray CJ, López AD: Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997, 349:1269-1276.
4. Geiss LS, Herman WH, Smith PJ: Mortality in non-insulin-dependent diabetes. In Diabetes in America, EDN 2. Edited by National Diabetes Data Group. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1995:233-258. NIH publication 95-1468.
5. Folsom AR, Rasmussen ML, Chambless ME, et al.: Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999, 22:1077-1083.
6. Katakura M, Naka M, Kondo T, et al.: Prospective analysis of mortality, morbidity, and risk factors in elderly diabetic subjects: Nagano study. Diabetes Care 2003, 26:638-644.
7. Currie CJ, Morgan CL, Gill L, et al.: Epidemiology and costs of acute hospital care for cerebrovascular disease in diabetic and nondiabetic populations. Stroke 1997, 28:1142-1146.
8. Luchsinger JA, Tang MX, Stern Y, et al.: Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001, 154:635-641.
9. Stamler J, Vaccaro O, Neaton JD, et al.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
10. Rohr J, Kittner S, Feeser B, et al.: Traditional risk factors and ischemic stroke in young adults: the Baltimore-Washington Cooperative Young Stroke Study. Arch Neurol 1996, 53:603-607.
11. Hankey GJ, Jamrozik K, Broadhurst RJ, et al.: Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998, 29:2491-2500.
12. Koren-Morag N, Goldbourt U, Tanne D: Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005, 36:1366.
13. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
14. Olijhoek JK, van der Graaf Y, Banga JD, et al.: The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004, 25:342-348.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
16. Oppenheimer S, Halfbraid BI, Oswald GA, Yudkin JS: Diabetes mellitus and early mortality from stroke. Br Med J 1985, 291:1014-1015.
17. Oliveira TV, Gorz AM, Bittencourt PR: [Diabetes mellitus as a prognostic factor in ischemic cerebrovascular disease. J Arq Neuropsiquiatr 1988, 46:287-291.
18. Sprafka JM, Virnig BA, Shahar E, McGovern PG: Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: the Minnesota Heart Survey. Diabetes Med 1994, 11:678-684.
19. Olsson T, Vitanen M, Asplund K, et al.: Prognosis after stroke in diabetic patients. A controlled prospective study. Diabetologia 1990, 33:244-249.
20. Sacco RL, Boden-Albala B, Abel G, et al.: Race-ethnic disparities in the impact of stroke risk factors: the Northern Manhattan Stroke Study. Stroke 2001, 32:1725-1731.
21. Rodriguez BL, D'Agostino R, Abbott RD, et al.: Risk of hospitalized stroke in men enrolled in the Honolulu Heart program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke 2002, 33:230-236.
22. Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823-828.
23. Eckel RH, Krauss RM: American Heart Association call to action obesity as a major risk factor for coronary heart disease. Circulation 1998, 97:2099-2100.
24. Lithner F, Asplund K, Eriksson S, et al.: Clinical characteristics in diabetic stroke patients. Diabetes Metab 1988, 4:15-19.
25. Roehmboldt ME, Palumbo PJ, Whisnant JP, Elveback LP: Transient ischemic attack and stroke in a community-based diabetic cohort. Mayo Clin Proc 1983, 58:56-58.
26. Abbott RD, Donahue RO, MacMahon SW, et al.: Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA 1987, 257:949-952.
27. Njolstad I, Arnesen E, Lund-Larsen PG: Body height, cardiovascular risk factors, and risk of stroke in middle-aged men and women. A 14-year follow-up of the Finnmark Study. Circulation 1996, 94:2877-2882.
28. Neaton JD, Wentworth DN, Cutler J, et al.: Multiple Risk Factor Intervention Trial Research Group. Risk factors for death from different types of stroke. Ann Epidemiol 1993, 3:493-499.
29. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS: The Copenhagen Stroke Study. Stroke in patients with diabetes. Stroke 1994, 25:1977-1984.
30. Eguchi K, Kario K, Shimada K: Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke 2003, 34:2471-2474.
31. Gandolfo C, Caponnetto C, Del Sette M, et al.: Risk factors in lacunar syndromes: a case-control study. Acta Neurol Scand 1988, 77:22-26.
32. Mast H, Thompson JL, Lee SH, et al.: Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. Stroke 1995, 26:30-33.
33. Tuszynski MH, Petito CK, Levy DE: Risk factors and clinical manifestations of pathologically verified lacunar infarctions. Stroke 1989, 20:990-999.
34. Arboix A, Padilla I, Massons J, et al.: Clinical study of 222 patients with pure motor stroke. J Neurol Neurosurg Psychiatry 2001, 71:239-242.
35. Kappelle LJ, van Gijn J: Lacunar infarcts. Clin Neurol Neurosurg 1986, 17:3-17.
36. Rovlias A, Kotsou S: The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery 2000, 46:335-342.
37. Abu-Lebdeh HS, Hodge DO, Nguyen TT: Predictors of macrovascular disease in patients with type 2 diabetes mellitus. Mayo Clin Proc 2001, 76:707-712.
38. Capes SE, Hunt D, Malmberg K, et al.: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001, 32:2426-2432.
39. Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996, 27:63-68.
40. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly patients. Stroke 1994, 25:1157-1164.
41. Haheim LL, Holme I, Hjermann I, Leren P: Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the Oslo Study. Stroke 1995, 26:774-777.
42. Lowe LP, Liu K, Greenland P, et al.: The Chicago Heart Association Detection Project in Industry Study. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. Diabetes Care 1997, 20:163-169.
43. Staaf G, Lindgren A, Norrving B: Pure motor stroke from presumed lacunar infarct. Long-term prognosis for survival and risk of recurrent stroke. Stroke 2001, 32:2592-2596.
44. Christensen H, Boysen G, Johannesen H, et al.: Deteriorating ischaemic stroke. cytokines, soluble cytokine receptors, ferritin, systemic blood pressure, body temperature, blood glucose, diabetes, stroke severity, and CT infarction-volume as predictors of deteriorating ischaemic stroke. J Neurol Sci 2002, 201:1-7.
45. Williams LS, Rotich J, Qi R, et al.: Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002, 59:67-71.
46. Woo J, Lam CWK, Kay R, et al.: The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol 1990, 47:1174-1177.
47. Passero S, Ciacci G, Ulivelli M: The influence of diabetes and hyperglycemia on clinical course after intracerebral hemorrhage. Neurology 2003, 25:1351-1356.
48. O'Neil PA, Davies I, Fullerton KJ, Bennett D: Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 1991, 22:842-847.
49. Berger L, Hakim AM: The association of hyperglycemia with cerebral edema in stroke. Stroke 1986, 17:865-871.
50. Szczudlik A, Slowik A, Turaj W: Transient hyperglycemia in ischemic stroke patients. J Neurol Sci 2001, 189:105-111.
51. Jorgensen HS, Reith J, Nakayama H, et al.: Potentially reversible factors during the very acute phase of stroke and their impact on the prognosis: is there a large therapeutic potential to be explored? Cerebrovasc Dis 2001, 11:207-211.
52. Toni D, Sacchetti ML, Argentino C, et al.: Does hyperglycemia play a role on the outcome of acute ischaemic stroke patients? J Neurol 1992, 239:382-386.
53. Haheim LL, Holme I, Hjermann I, Leren P: Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the Oslo Study. Stroke 1995, 26:774-777.
54. Oppenheimer S, Halfbraid BI, Oswald GA, Yudkin JS: Diabetes mellitus and early mortality from stroke. BMJ 1985, 291:1014-1015.
55. Pulsinelli WA, Levy DE, Sigsbee B, et al.: Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 1983, 74:540-544.
56. Hankey GJ, Jamrozik K, Broadhurst RJ, et al.: Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998, 29:2491-2500.
57. Sacco RL, Foulkes MA, Mohr JP, et al.: Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989, 20:983-989.
58. Jorgensen HS, Nakayama H, Reith J, et al.: Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997, 48:891-895.
59. Carlberg B, Asplund K, Hagg E: Factors influencing admission blood pressure levels in patients with acute stroke. Stroke 1991, 22:527-530.
60. Lefkovits J, Davis SM, Rossiter SC, et al.: Acute stroke outcome: effects of stroke type and risk factors. Aust N Z J Med 1992, 22:30-35.
61. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
62. Luchsinger JA, Tang MX, Shea S, Mayeux R: A recent study has demonstrated that hyperinsulinemia is associated with a higher risk of AD and decline in memory. (Hyperinsulinemia and risk of Alzheimer disease). Neurology 2004, 63:1187-1192.
63. Lindeman RD, Romero LJ, LaRue A, et al.: A biethnic community survey of cognition in participants with type 2 diabetes, impaired glucose tolerance, and normal glucose tolerance: the New Mexico Elder Health Survey, Diabetes Care 2001, 24:1567-1572.
64. Leibson CL, Rocca WA, Hanson VA, et al.: Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997, 145:301-308.
65. Ott A, Stolk RP, van Harskamp F, et al.: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937-1942.
66. Selkoe DJ: The origins of Alzheimer disease: a is for amyloid. JAMA 2000, 283:1615-1617.
67. Park CR: Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 2001, 25:311-323.
68. Farris W, Mansourian S, Chang Y, et al.: Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003, 100:4162-4164.
69. Weinberger J, Biscarra V, Weisberg MK, et al.: Factors contributing to stroke in patients with atherosclerotic disease of the great vessels: the role of diabetes. Stroke 1983, 14:709-712.
70. Abizaid A, Costa MA, Centemero M, et al.: Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Insights from the Arterial Revascularization Therapy Study (ARTS) Trial. Circulation 2001, 104:533-538.
71. Elmore EM, Mosquera A, Weinberger J: The prevalence of asymptomatic intracranial large-vessel occlusive disease: the role of diabetes. J Neuroimaging 2003, 13:224-227.
72. Engerman RL, Kern TS, Larson ME: Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 1994, 37:141-144.
73. Lee AY, Chung SK, Chung SS: Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA 1995, 92:2780-2784.
74. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
75. UK Prospective Diabetes Study (UKDPS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKDPS 33). Lancet 1998, 352:837-852.
76. Heart Outcome Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Study. Lancet 2000, 55:253-259.
77. Yusuf S, Sleight F, Pogue J, et al.: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
78. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:995-1003.
79. Ibsen H, Lindholm LH, Pedersen OL, et al.: [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study. J Ugeskr Laeger 2003, 165:459-462.
80. The Scandinavian Simvastatin Survival Study (4S): Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994, 344:1383-1389.